DHDaisy Ann Hoagland

Daisy Ann Hoagland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daisy Ann Hoagland has a total of 240 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional chimeric mRNAs encode proteins in mammalian immunity

    by Olivia Venezia, Harry Kane, Gang Du, Hannah D. Coughlan, Timothy M. Johanson, Hongshen Wang, Pathricia Tilstam, Samuel W. Kazer, Georgia Gunner, Daisy A. Hoagland, et al.

    Individual mammalian mRNAs and proteins are typically believed to originate from single genomic loci, with isoform diversity arising through cis -splicing of pre-mRNA. Whether mRNA from distant genes can undergo trans -splicing to generate functionally relevant chimeric transcripts has remained unclear. Here we develop a pipeline combining long-read direct RNA sequencing with non-targeted and targeted validation to identify chimeric transcripts in macrophages. Chromatin conformation capture studies reveal that inflammation induces interchromosomal DNA interactions, positioning parent genes proximally to facilitate the formation of chimeric mRNA. Notably, we identify a protein-coding chimeric mRNA representing a fusion between the pore-forming protein gasdermin D (GSDMD) 1,2 and a C-terminal domain translated out of frame from Tmem106a ( Gsdmd - Tmem106a ) in mice. We show that inflammasome priming upregulates Gsdmd - Tmem106a , with the protein localizing to the plasma membrane. After activation of the inflammasome, GSDMD–TMEM106A directly interacts with canonical GSDMD N termini to accelerate and enhance pore formation and IL-1β release. Finally, we show that GSDMD–TMEM106A balances host defence and immunopathology in vivo: its loss protects against lethal sepsis but compromises antibacterial defence, whereas overexpression enhances host protection while increasing sepsis lethality. We establish that protein-coding chimeric mRNAs formed by regulated transcript fusion events are operative during inflammation and immunity.


  • Open Access

    Type I interferon primes the alveolar epithelium to receive reparative signals from tissue-resident macrophages

    by Alan Y. Baez Vazquez, Daisy A. Hoagland, Alexander O. Mann, Yunkang Lin, Susanna M. Dang, Max Hauptschein, Louison Thorens, Shahinoor Begum, Martha A. Castro, Patricia Rodríguez-Morales, et al.

    Lung repair in response to viral infection requires integrated communication between epithelial and immune compartments, yet the impact of antiviral mediators on epithelial regenerative capacity remains poorly defined. Here, we demonstrate that type I interferon (IFN-I) signaling primes the lung for alveolar renewal following viral challenge. IFN-I contributes to the induction of an interferon-stimulated gene-high (ISG) hi Sca-1 Pos population of alveolar type II (ATII) epithelial cells. Sca-1 Pos ATIIs exhibit enhanced proliferative capacity and increased organoid-forming efficiency compared with their Sca-1 Neg counterparts. Viral challenge concurrently drives phenotypic reprogramming of tissueresident alveolar macrophages (trAMs). Sca-1 Pos ATIIs display heightened responsiveness to oncostatin M (OSM) and, following viral challenge, require trAM-derived OSM for their proliferation. Together, these findings reveal that viral stimuli induce coordinated IFN-I-dependent epithelial and macrophage states that poise the lung for regeneration, positioning IFN-I not only as a central antiviral defense mechanism but as a priming signal that prepares lung tissue for renewal.

  • Open Access

    In vivo interrogation of transcriptional and epigenetic regulators of lung epithelial regeneration

    by Dawei Sun, Daisy Ann Hoagland, Daniel Strebinger, Chenlei Hu, Benno C. Orr, Shahinoor Begum, Giovanni Marrero, Jackson A. Weir, Ruth A Franklin, Fei Chen

    Effective alveolar repair after viral lung injury requires precise coordination of alveolar type 2 cell (AT2) proliferation and differentiation to restore lung function. To uncover causal regulators of this process in the native tissue environment, we developed SAGE (Stable Adeno-Associated Virus Genomic IntEgration), an engineered AAV system that enables high-throughput in vivo genetic interrogation. SAGE supports both bulk phenotypic screening (SAGE-Perturb) and single-cell transcriptomic profiling (SAGE-Perturb-seq). Using this approach, we identified lysine acetyltransferase 8 (Kat8) as essential for epithelial repair following viral infection through the Non-Specific-Lethal (NSL) complex, and generated a time-resolved, high-resolution functional map of transcription factor knockouts during alveolar repair, revealing transcription factor dependences for distinct alveolar epithelial repair trajectories. This map further defined two independent AT2-derived transitional states: a reparative state, and a pathological state that is transcriptionally similar to the basaloid population observed in human pulmonary fibrosis. Disruption of transcription factors in the NF-𝜅B pathway prevented the emergence of the pathological transitional state, linking inflammation and maladaptive epithelial remodeling. SAGE represents a versatile platform for functional genomics in vivo, with applications extending across respiratory biology and disease.

  • Vagal TRPV1 + sensory neurons protect against influenza virus infection by regulating lung myeloid cell dynamics

    by Nicole Almanzar, Daping Yang, Jingya Xia, Swalpa Udit, Prabhu Joshi, Sandeep Adhikari, Daisy A. Hoagland, Stephen T. Yeung, Camille Khairallah, Tomas Huerta, et al.

    Influenza viruses are a major global cause of morbidity and mortality. Although vagal TRPV1 + nociceptive sensory neurons are known to mediate defenses against harmful agents, including pathogens, their function in lung antiviral defenses remains unclear. Our study demonstrates that both systemic and vagal-specific ablation of TRPV1 + nociceptors reduce survival in mice infected with influenza A virus (IAV). Despite no difference in viral load, mice lacking TRPV1 + neurons exhibited increased viral spread, exacerbated lung pathology, and elevated levels of proinflammatory cytokines. Loss of TRPV1 + neurons altered the lung immune landscape, including an expansion of neutrophils and monocyte-derived macrophages. Transcriptional analysis revealed impaired interferon signaling in myeloid cells and an imbalance in distinct neutrophil subpopulations in the absence of nociceptors. Furthermore, antibody-mediated depletion of myeloid cells during IAV infection substantially improved survival after nociceptor ablation, underscoring the role of TRPV1 + neurons in preventing pathogenic myeloid cell states that contribute to IAV-induced mortality.


  • Top Cited Papers

    Macrophage-derived oncostatin M repairs the lung epithelial barrier during inflammatory damage

    by Daisy A. Hoagland, Patricia Rodríguez-Morales, Alexander O. Mann, Alan Y. Baez Vazquez, Shuang Yu, Alicia Lai, Harry Kane, Susanna M. Dang, Yunkang Lin, Louison Thorens, et al.

    Tissue repair programs must function alongside antiviral immunity to restore the lung epithelial barrier following infection. We found that macrophage-derived oncostatin M (OSM) counteracted the pathological effects of type I interferon (IFN-I) during infection and damage in mice. At baseline, OSM-deficient mice exhibited altered alveolar type II (ATII) epithelial cell states. In response to influenza or viral mimic challenge, mice lacking OSM exhibited heightened IFN-I responses and increased mortality. OSM delivery to the lung induced ATII proliferation and was sufficient to protect deficient mice against morbidity. Furthermore, OSM promoted organoid formation despite the growth-inhibitory effects of IFN-I. These findings identify OSM as an indispensable macrophage-derived growth factor that maintains the homeostasis of lung epithelial cells and promotes their proliferation to overcome IFN-I–mediated immunopathology.


  • Open Access

    A genetically based computational drug repurposing framework for rapid identification of candidate compounds: application to COVID-19

    by Georgios Voloudakis, Kyung Min Lee, James M. Vicari, Wen Zhang, Daisy Hoagland, Sanan Venkatesh, Jiantao Bian, Marios Anyfantakis, Zhenyi Wu, Samir Rahman, et al.

    Background: The development and approval of novel drugs are typically time-intensive and expensive. Leveraging a computational drug repurposing framework that integrates disease-relevant genetically regulated gene expression (GReX) and large longitudinal electronic medical record (EMR) databases can expedite the repositioning of existing medications. However, validating computational predictions of the drug repurposing framework remains a challenge. Methods: To benchmark the drug repurposing framework, we first performed a 5-method-rank-based computational drug prioritization pipeline by integrating multi-tissue GReX associated with COVID-19-related hospitalization, with drug transcriptional signature libraries from the Library of Integrated Network-Based Cellular Signatures. We prioritized FDA-approved medications from the 10 top-ranked compounds, and assessed their association with COVID-19 incidence within the Veterans Health Administration (VHA) cohort (~9 million individuals). In parallel, we evaluated in vitro SARS-CoV-2 replication inhibition in human lung epithelial cells for the selected candidates. Results: Our in silico pipeline identified seven FDA-approved drugs among the top ten candidates. Six (imiquimod, nelfinavir and saquinavir, everolimus, azathioprine, and retinol) had sufficient prescribing rates or feasibility for further testing. In the VHA cohort, azathioprine (odds ratio [OR]=0.69, 95% CI 0.62–0.77) and retinol (OR=0.81, 95% CI 0.72–0.92) were significantly associated with reduced COVID-19 incidence. Conversely, nelfinavir and saquinavir demonstrated potent SARS-CoV-2 inhibition in vitro (~95% and ~65% viral load reduction, respectively). No single compound showed robust protection in both in vivo and in vitro settings. Conclusions: These findings underscore the power of GReX-based drug repurposing in rapidly identifying existing therapies with potential clinical relevance; four out of six compounds showed a protective effect in one of the two validation approaches. Crucially, our results highlight how a complementary evaluation—combining epidemiological data and in vitro assays—helps refine the most promising candidates for subsequent mechanistic studies and clinical trials. This integrated validation approach may prove vital for accelerating therapeutic development against current and future health challenges.


  • Open Access

    Macrophages control pathological interferon responses during viral respiratory infection

    by Daisy A. Hoagland, Patricia Rodríguez-Morales, Alexander O. Mann, Shuang Yu, Alicia Lai, Alan Baez Vazquez, Scott D. Pope, Jaechul Lim, Shun Li, Xian Zhang, et al.

    Antiviral immune mediators, including interferons and their downstream effectors, are critical for host defense yet can become detrimental when uncontrolled. Here, we identify a macrophage-mediated anti-inflammatory mechanism that limits type I interferon (IFN-I) responses. Specifically, we found that cellular stress and pathogen recognition induce Oncostatin M (OSM) production by macrophages. OSM-deficient mice succumbed to challenge with influenza or a viral mimic due to heightened IFN-I activation. Macrophage-derived OSM restricted excessive IFN-I production by lung epithelial cells following viral stimulation. Furthermore, reconstitution of OSM in the respiratory tract was sufficient to protect mice lacking macrophage-derived OSM against morbidity, indicating the importance of local OSM production. This work reveals a host strategy to dampen inflammation in the lung through the negative regulation of IFN-I by macrophages. One-Sentence Summary Type I interferons induced by viral stimuli are negatively regulated by macrophage-derived Oncostatin M.


  • Top Cited Papers
    Open Access

    SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery

    by Justin J. Frere, Randal A. Serafini, Kerri D. Pryce, Marianna Zazhytska, Kohei Oishi, Ilona Golynker, Maryline Panis, Jeffrey Zimering, Shu Horiuchi, Daisy A. Hoagland, et al.

    The host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can result in prolonged pathologies collectively referred to as post-acute sequalae of COVID-19 (PASC) or long COVID. To better understand the mechanism underlying long COVID biology, we compared the short- and long-term systemic responses in the golden hamster after either SARS-CoV-2 or influenza A virus (IAV) infection. Results demonstrated that SARS-CoV-2 exceeded IAV in its capacity to cause permanent injury to the lung and kidney and uniquely affected the olfactory bulb (OB) and olfactory epithelium (OE). Despite a lack of detectable infectious virus, the OB and OE demonstrated myeloid and T cell activation, proinflammatory cytokine production, and an interferon response that correlated with behavioral changes extending a month after viral clearance. These sustained transcriptional changes could also be corroborated from tissue isolated from individuals who recovered from COVID-19. These data highlight a molecular mechanism for persistent COVID-19 symptomology and provide a small animal model to explore future therapeutics.


  • Top Cited Papers

    Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia

    by Marianna Zazhytska, Albana Kodra, Daisy A. Hoagland, Justin Frere, John F. Fullard, Hani Shayya, Natalie G. McArthur, Rasmus Moeller, Skyler Uhl, Arina D. Omer, et al.


  • Open Access

    IL10RB as a key regulator of COVID-19 host susceptibility and severity

    by Georgios Voloudakis, Gabriel Hoffman, Sanan Venkatesh, Kyung Min Lee, Kristina Dobrindt, James M. Vicari, Wen Zhang, Noam D. Beckmann, Shan Jiang, Daisy Hoagland, et al.

    Background: Recent efforts have identified genetic loci that are associated with coronavirus disease 2019 (COVID-19) infection rates and disease outcome severity. Translating these genetic findings into druggable genes and readily available compounds that reduce COVID-19 host susceptibility is a critical next step. Methods: We integrate COVID-19 genetic susceptibility variants, multi-tissue genetically regulated gene expression (GReX) and perturbargen signatures to identify candidate genes and compounds that reverse the predicted gene expression dysregulation associated with COVID-19 susceptibility. The top candidate gene is validated by testing both its GReX and observed blood transcriptome association with COVID-19 severity, as well as by in vitro perturbation to quantify effects on viral load and molecular pathway dysregulation. We validate the in silico drug repositioning analysis by examining whether the top candidate compounds decrease COVID-19 incidence based on epidemiological evidence. Results: We identify IL10RB as the top key regulator of COVID-19 host susceptibility. Predicted GReX up-regulation of IL10RB and higher IL10RB expression in COVID-19 patient blood is associated with worse COVID-19 outcomes. In vitro IL10RB overexpression is associated with increased viral load and activation of immune-related molecular pathways. Azathioprine and retinol are prioritized as candidate compounds to reduce the likelihood of testing positive for COVID-19. Conclusions: We establish an integrative data-driven approach for gene target prioritization. We identify and validate IL10RB as a suitable molecular target for modulation of COVID-19 host susceptibility. Finally, we provide evidence for a few readily available medications that would warrant further investigation as drug repositioning candidates.